Remicade and Retinal degeneration - a phase IV clinical study of FDA data

Summary:

Retinal degeneration is reported as a side effect among people who take Remicade (infliximab), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Humira, and have Fibromyalgia.

The phase IV clinical study analyzes which people have Retinal degeneration when taking Remicade. It is created by eHealthMe based on reports of 222,651 people who have side effects when taking Remicade from the FDA, and is updated regularly.

What is Remicade?

Remicade has active ingredients of infliximab. It is often used in crohn's disease. eHealthMe is studying from 224,011 Remicade users. Check the latest studies of Remicade.

What is Retinal degeneration?

Retinal degeneration (death of the cells of the retina) is found to be associated with 160 drugs and 316 conditions by eHealthMe. Check the latest studies of Retinal degeneration.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

222,651 people reported to have side effects when taking Remicade.
Among them, 12 people (0.01%) have Retinal degeneration.

Could Remicade cause Retinal degeneration?

Among these 12 people:

How long have people been on Remicade when they have Retinal degeneration? *

What is the gender of people who have Retinal degeneration when taking Remicade? *

female: 75 %
male: 25 %

What is the age of people who have Retinal degeneration when taking Remicade? *

What are other drugs people take besides Remicade? *

What are other side effects people have besides Retinal degeneration? *

Hypoaesthesia (reduced sense of touch or sensation): 7 people, 58.33%
Fainting (loss of consciousness and postural tone): 7 people, 58.33%
Joint Range Of Motion Decreased (disease of joint movement): 7 people, 58.33%
Iron Deficiency Anaemia: 7 people, 58.33%
Infection: 7 people, 58.33%
Impaired Gastric Emptying: 7 people, 58.33%
Hyperlipidaemia (presence of excess lipids in the blood): 7 people, 58.33%
Hepatic Enzyme Increased: 7 people, 58.33%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 7 people, 58.33%
Hearing Loss: 7 people, 58.33%

What are the existing conditions these people have? *

Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 1 person, 8.33%
Limb Discomfort (discomfort in leg): 1 person, 8.33%
Hypersensitivity: 1 person, 8.33%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Remicade and have Retinal degeneration?

- Check whether Retinal degeneration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remicade:

Remicade (224,011 reports)

Browse all side effects of Remicade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinal degeneration:

Retinal degeneration (160 drugs)

Browse all the conditions that are associated with Retinal degeneration:

Retinal degeneration (316 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on infliximab (the active ingredients of Remicade) and Remicade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.